affiliate disclosure · We earn affiliate commission on some vendor links. Audits, scores, and rankings are independent — vendors do not pay for placement and do not see drafts. read more →
A literature read of the side-effect profile from Eli Lilly's published Phase 2 and TRIUMPH Phase 3 retatrutide data — GI events, the heart-rate signal, dose-titration tolerability, and the dimensions still being characterized.
The Phase 2 retatrutide publication (Jastreboff et al., NEJM 2023); the TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-4 Phase 3 readouts published through April 2026; Eli Lilly's quarterly investor presentations referencing the program; and the ClinicalTrials.gov entries for the TRIUMPH program (NCT05882045, NCT05952713, NCT05882187, NCT05996731). This is a literature synthesis, not a clinical-practice document.
Retatrutide is a triple receptor agonist — it activates the GLP-1, GIP, and glucagon receptors. The first two receptors are familiar from semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP). The third receptor — glucagon — is what distinguishes retatrutide both clinically and in its side-effect profile.
Glucagon-receptor activation increases energy expenditure (the body burns more), which is part of why the published weight-loss curve continues sloping past the 48-week mark in retatrutide trials when GLP-1-only and GLP-1+GIP curves have begun to plateau. The same mechanism produces a modest cardiovascular signal that distinguishes retatrutide's safety profile from the predecessor compounds.
Across the TRIUMPH readouts available through April 2026, the side-effect profile clusters into four categories. Each is reported at frequencies broadly comparable to tirzepatide SURMOUNT figures except where noted.
GI side effects are the most-reported category across all GLP-1-class compounds, and retatrutide is no exception. Published Phase 3 frequencies:
GI events are typically transient and concentrated in the dose-escalation phase. Tolerability improves at maintenance doses. The trial protocols use slower-than-typical titration schedules specifically to manage this.
This is the side-effect category that distinguishes retatrutide from tirzepatide and semaglutide. The published Phase 3 readouts show a 1–3 bpm mean increase in resting heart rate across the reported populations, dose-dependent, attributable to the glucagon-receptor activity.
The magnitude is modest. The clinical question — whether this signal translates into adverse cardiovascular outcomes at scale — is what TRIUMPH-5 is specifically designed to answer. As of April 2026, the TRIUMPH-5 efficacy readout against placebo for major adverse cardiovascular events is not yet published. Interim safety readouts have been acceptable; the headline outcome data is forthcoming.
This dimension is what differentiates retatrutide's safety profile from the GLP-1-only and GLP-1+GIP class members. Buyers reading the literature should hold this as the most important pending question.
Reported at frequencies broadly comparable to tirzepatide and semaglutide injection-site rates. Most are mild — transient erythema, minor induration, occasional pruritus at the injection site. Discontinuation due to injection-site reactions is uncommon in the published data.
The TRIUMPH Phase 3 readouts report discontinuation rates due to adverse events broadly comparable to tirzepatide SURMOUNT figures. This is meaningful given that retatrutide produces a larger weight-loss effect — the trade-off in tolerability is not, by the published data, proportional to the additional efficacy.
Three categories the published TRIUMPH program does not yet fully address:
Long-term durability beyond 88 weeks. The longest published extension data covers 88 weeks. Whether the side-effect profile remains stable beyond that window — particularly the heart-rate signal — is a published-data gap that ongoing extension studies will fill in over 2026–2028.
Cardiovascular outcomes at scale. TRIUMPH-5 is the trial designed to answer this. The interim safety readouts are acceptable; the efficacy readout against placebo for major adverse cardiovascular events is the bar GLP-1-class drugs face for any cardio-protective labeling. This data is not yet public.
Special populations. Pediatric, hepatic-impairment, and pregnant populations are not covered by the published TRIUMPH program. These are typical post-approval study commitments rather than Phase 3 program exclusions, but the side-effect profile in these populations is not yet characterized.
A clean side-by-side on the dimensions that drive tolerability decisions:
| Dimension | Semaglutide | Tirzepatide | Retatrutide | |---|---|---|---| | Mechanism | GLP-1 mono-agonist | GLP-1 + GIP dual-agonist | GLP-1 + GIP + glucagon triple-agonist | | Peak Phase 3 weight loss (top dose, 48wk) | ~15% | ~21% | ~24% | | GI side-effect profile | Class-typical | Class-typical | Class-typical | | Heart-rate signal | Not characteristic | Not characteristic | 1–3 bpm elevation (glucagon) | | Discontinuation-due-to-AE rate | Class-typical | Class-typical | Comparable to tirzepatide | | FDA approval | Yes (Wegovy 2021) | Yes (Zepbound 2023) | No — Phase 3, FDA submission targeted 2026 |
The heart-rate signal is the single most important comparative distinction. Everything else in the published profile clusters near the tirzepatide reference figures.
Research-peptide retatrutide is not the same data point. The Phase 3 trials test pharma-grade retatrutide produced under cGMP conditions and titrated under medical supervision. Research-peptide samples sold outside that framework are subject to manufacturing variance, identity-confirmation gaps, and dose-titration without clinical oversight. The Janoshik 7,164-tests purity analysis documents the cross-vendor variance specifically for retatrutide: of the 200 publicly-submitted tests in our local mirror, retatrutide is the most-tested compound (44 tests) and historically had higher purity variance than tirzepatide.
The side-effect profile in the trials does not extrapolate to research-peptide use. Compound identity is the first variable; dose titration without clinical oversight is the second.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.